🌶️Pepperpedia
Community(soon)

Bile Acid Synthesis

From Pepperpedia, the free peptide encyclopedia
Bile Acid Synthesis
Properties
CategoryMechanisms
Also known asbile acid biosynthesis
Last updated2026-04-14
Reading time4 min read
Tags
mechanismmetabolismlipid

Overview

Bile acid synthesis is the hepatic pathway that converts cholesterol into bile acids, which serve as emulsifiers for dietary fat absorption and, increasingly appreciated, as signaling molecules. Bile acid synthesis accounts for the majority of daily cholesterol disposal (roughly 500 mg/day in a typical adult), making it a major regulator of whole-body cholesterol balance alongside biliary and fecal neutral sterol excretion.

The two primary bile acids synthesized in the human liver are cholic acid and chenodeoxycholic acid. After synthesis, they are conjugated to glycine or taurine, secreted into bile, stored in the gallbladder, and released into the small intestine with meals. Intestinal bacteria further modify them to secondary bile acids (deoxycholic acid, lithocholic acid). Most bile acids are reabsorbed in the terminal ileum and return to the liver through portal circulation (enterohepatic circulation), with only a small fraction lost in stool.

Bile acids act as ligands for the nuclear receptor FXR (farnesoid X receptor) and the membrane receptor TGR5 (GPBAR1). Through these receptors, bile acids regulate their own synthesis (feedback via FXR and FGF19), lipid and glucose metabolism, inflammation, and thermogenesis. Drugs targeting bile acid signaling are approved for primary biliary cholangitis and are being developed for NAFLD/NASH and metabolic disease.

Mechanism / Process

  1. Two pathways. The classical (neutral) pathway begins with the microsomal enzyme cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting and regulated step. The alternative (acidic) pathway begins with side-chain oxidation by sterol 27-hydroxylase (CYP27A1), making oxysterol intermediates.

  2. Classical pathway. CYP7A1 hydroxylates cholesterol at the 7-alpha position. Further modifications by CYP8B1 (12-alpha-hydroxylase, directing synthesis toward cholic versus chenodeoxycholic acid), 3-beta-hydroxy-delta-5-C27-steroid oxidoreductase (HSD3B7), and others construct the bile acid nucleus. Peroxisomal side-chain shortening completes the 24-carbon bile acid backbone.

  3. Alternative pathway. CYP27A1 oxidizes the side chain first, producing 27-hydroxycholesterol that proceeds through CYP7B1 and subsequent steps. This pathway is a smaller contributor in adults but important in specific tissues and contexts.

  4. Conjugation. Bile acid-CoA:amino acid N-acyltransferase (BAAT) conjugates bile acids to glycine or taurine via their bile acyl-CoA intermediates, increasing solubility and preventing passive absorption.

  5. Secretion. Conjugated bile acids are exported across the canalicular membrane into bile by the bile salt export pump (BSEP/ABCB11). They are stored in the gallbladder, concentrated, and released into the duodenum with meals triggered by CCK.

  6. Intestinal action and bacterial modification. In the gut lumen, bile acids emulsify dietary lipids and activate pancreatic lipase activity. Intestinal bacteria deconjugate and 7-alpha-dehydroxylate primary bile acids, producing secondary bile acids.

  7. Enterohepatic circulation. In the terminal ileum, the apical sodium-dependent bile acid transporter (ASBT/SLC10A2) reabsorbs bile acids. They return to the liver via portal blood, where NTCP and OATPs take them back into hepatocytes for re-secretion.

  8. Regulation. FXR in enterocytes induces FGF19, which travels to the liver and suppresses CYP7A1 through FGFR4/beta-Klotho signaling. FXR in hepatocytes directly suppresses CYP7A1 via SHP. Bile acids thus negatively feedback on their own synthesis.

Key Players / Molecular Components

  • CYP7A1 and CYP27A1. Rate-limiting enzymes of the classical and alternative pathways.
  • CYP8B1. 12-alpha-hydroxylase; directs ratio of cholic to chenodeoxycholic acid.
  • BAAT. Conjugation enzyme.
  • BSEP (ABCB11). Canalicular bile acid exporter; mutations cause progressive familial intrahepatic cholestasis type 2.
  • ASBT (SLC10A2), NTCP (SLC10A1), OATP1B1/1B3. Enterohepatic transporters.
  • FXR (NR1H4) and TGR5 (GPBAR1). Bile acid receptors.
  • FGF19/FGF15 and FGFR4/beta-Klotho. Gut-liver hormonal axis.

Clinical Relevance / Therapeutic Targeting

Bile acid dysregulation underlies cholestatic diseases (primary biliary cholangitis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis). Obeticholic acid, a chenodeoxycholic acid analog and FXR agonist, is approved for primary biliary cholangitis and was studied in NASH. Bile acid sequestrants (cholestyramine, colesevelam) bind intestinal bile acids to reduce LDL cholesterol and can treat bile acid diarrhea. Ursodeoxycholic acid treats cholestatic liver disease. ASBT inhibitors (odevixibat, maralixibat) treat pruritus in PFIC and Alagille syndrome. Bile acid signaling via TGR5 influences energy expenditure and glucose metabolism, motivating interest in metabolic disease.

Peptides That Target This Pathway

  • FGF19 analogs — mimic enterohepatic signaling to suppress bile acid synthesis.
  • GLP-1 analogs — indirectly modulate bile acid physiology through metabolic improvement.
  • CCK — triggers gallbladder contraction and bile release.
  • Secretin — modulates bile composition.
  • FGF21 — metabolic hormone related to bile acid regulation and FGF19 signaling.

Related entries

  • Fatty Acid Synthesis— Fatty acid synthesis is the metabolic pathway that converts excess dietary carbohydrates and amino acids into fatty acids for energy storage, membrane synthesis, and signaling — a process tightly regulated by insulin and relevant to metabolic peptide therapeutics.
  • Cholesterol Synthesis— The multi-step pathway that builds cholesterol from acetyl-CoA through the mevalonate intermediate, the target of statin drugs.
  • Fatty Acid Synthesis— The cytoplasmic pathway that builds long-chain fatty acids from acetyl-CoA, coordinated with dietary and hormonal signals.
  • Insulin Receptor Pathway— The insulin receptor pathway translates circulating insulin into coordinated cellular responses that govern glucose uptake, lipid storage, protein synthesis, and growth.
  • Steroidogenesis— The enzymatic conversion of cholesterol into steroid hormones in adrenal, gonadal, and other steroidogenic tissues.